Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Apr;117(7):1565–1571. doi: 10.1111/j.1476-5381.1996.tb15322.x

Haemodynamic and cardiac effects of kinin B1 and B2 receptor stimulation in conscious instrumented dogs.

P Bélichard 1, B Loillier 1, J L Paquet 1, J M Luccarini 1, D Pruneau 1
PMCID: PMC1909437  PMID: 8730755

Abstract

1. Mongrel dogs were chronically instrumented with an intra-aortic catheter, a Königsberg intraventricular pressure transducer and a Döppler flow probe around the left coronary artery. After ganglionic blockade with hexamethonium, the cardiovascular effects of bradykinin B1 and B2 receptor agonists, des-Arg9-bradykinin and bradykinin (BK), were investigated in the presence and absence of specific antagonists. The contribution of nitric oxide (NO) and prostanoids to the cardiovascular effects of kinins was also examined. 2. BK (1 microgram kg-1 min-1) and des-Arg9-BK (1 microgram kg-1 min-1) both given as a 2 min i.v. infusion, produced a significant decrease in mean arterial pressure (MAP, -34 +/- 4% for BK and -45 +/- 2% for des-Arg9-BK) and coronary vascular resistance (CVR, -37 +/- 5% for BK and -50 +/- 2% for des-Arg9-BK), without affecting cardiac contractility, left ventricular end diastolic pressure, and coronary velocity. BK caused a significantly greater decrease in MAP and CVR than des-Arg9-BK (P < 0.05). 3. Pretreatment with the B1 receptor antagonist, des-Arg9-[Leu8]-BK (25 micrograms kg-1) significantly inhibited the decrease in MAP and CVR produced by des-Arg9-BK but not by BK. Infusion of des-Arg9-[Leu8]-BK alone also induced a significant decrease in MAP and CVR (P < 0.05). In the presence of the B2 receptor antagonist, Hoe 140 (25 micrograms kg-1), only the decreases in MAP and CVR caused by BK were significantly reduced (P < 0.05). 4. Inhibition of NO synthase with N omega-nitro-L-arginine (L-NOARG, 45 mg kg-1) significantly (P < 0.05) prevented the decrease in CVR but not MAP induced by des-Arg9-BK, whilst responses to BK were not affected by L-NOARG pretreatment. Inhibition of prostanoid synthesis with indomethacin (25 mg kg-1) did not affect the reductions in MAP and CVR induced by des-Arg9-BK or BK. 5. In conclusion, i.v. des-Arg9-BK and BK administration induced reductions in MAP and CVR suggesting that in conscious instrumented dogs both B1 and B2 receptors are present and can affect systemic blood pressure and coronary resistance regulation. Our results also suggest that prostanoids are not involved in the vascular response to kinins and that coronary vascular B1 receptors are at least in part coupled to the release of NO.

Full text

PDF
1565

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berguer R., Hottenstein O. D., Palen T. E., Stewart J. M., Jacobson E. D. Bradykinin-induced mesenteric vasodilation is mediated by B2-subtype receptors and nitric oxide. Am J Physiol. 1993 Mar;264(3 Pt 1):G492–G496. doi: 10.1152/ajpgi.1993.264.3.G492. [DOI] [PubMed] [Google Scholar]
  2. Bouthillier J., Deblois D., Marceau F. Studies on the induction of pharmacological responses to des-Arg9-bradykinin in vitro and in vivo. Br J Pharmacol. 1987 Oct;92(2):257–264. doi: 10.1111/j.1476-5381.1987.tb11319.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bény J. L., Brunet P. C. Electrophysiological and mechanical effects of substance P and acetylcholine on rabbit aorta. J Physiol. 1988 Apr;398:277–289. doi: 10.1113/jphysiol.1988.sp017042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cherry P. D., Furchgott R. F., Zawadzki J. V., Jothianandan D. Role of endothelial cells in relaxation of isolated arteries by bradykinin. Proc Natl Acad Sci U S A. 1982 Mar;79(6):2106–2110. doi: 10.1073/pnas.79.6.2106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Clozel J. P., Roberts A. M., Hoffman J. I., Coleridge H. M., Coleridge J. C. Vagal chemoreflex coronary vasodilation evoked by stimulating pulmonary C-fibers in dogs. Circ Res. 1985 Sep;57(3):450–460. doi: 10.1161/01.res.57.3.450. [DOI] [PubMed] [Google Scholar]
  6. DeWitt B. J., Cheng D. Y., Kadowitz P. J. des-Arg9-bradykinin produces tone-dependent kinin B1 receptor-mediated responses in the pulmonary vascular bed. Circ Res. 1994 Dec;75(6):1064–1072. doi: 10.1161/01.res.75.6.1064. [DOI] [PubMed] [Google Scholar]
  7. Deblois D., Marceau F. The ability of des-Arg9-bradykinin to relax rabbit isolated mesenteric arteries is acquired during in vitro incubation. Eur J Pharmacol. 1987 Oct 6;142(1):141–144. doi: 10.1016/0014-2999(87)90664-9. [DOI] [PubMed] [Google Scholar]
  8. Drummond G. R., Cocks T. M. Endothelium-dependent relaxations mediated by inducible B1 and constitutive B2 kinin receptors in the bovine isolated coronary artery. Br J Pharmacol. 1995 Nov;116(5):2473–2481. doi: 10.1111/j.1476-5381.1995.tb15098.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Graier W. F., Schmidt K., Kukovetz W. R. Is the bradykinin-induced Ca2+ influx and the formation of endothelium-derived relaxing factor mediated by a G protein? Eur J Pharmacol. 1992 Jan 14;225(1):43–49. doi: 10.1016/0922-4106(92)90037-v. [DOI] [PubMed] [Google Scholar]
  10. Hall J. M. Bradykinin receptors: pharmacological properties and biological roles. Pharmacol Ther. 1992 Nov;56(2):131–190. doi: 10.1016/0163-7258(92)90016-s. [DOI] [PubMed] [Google Scholar]
  11. Hess J. F., Borkowski J. A., Young G. S., Strader C. D., Ransom R. W. Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem Biophys Res Commun. 1992 Apr 15;184(1):260–268. doi: 10.1016/0006-291x(92)91187-u. [DOI] [PubMed] [Google Scholar]
  12. Kiuchi K., Sato N., Shannon R. P., Vatner D. E., Morgan K., Vatner S. F. Depressed beta-adrenergic receptor- and endothelium-mediated vasodilation in conscious dogs with heart failure. Circ Res. 1993 Dec;73(6):1013–1023. doi: 10.1161/01.res.73.6.1013. [DOI] [PubMed] [Google Scholar]
  13. Lamontagne D., König A., Bassenge E., Busse R. Prostacyclin and nitric oxide contribute to the vasodilator action of acetylcholine and bradykinin in the intact rabbit coronary bed. J Cardiovasc Pharmacol. 1992 Oct;20(4):652–657. doi: 10.1097/00005344-199210000-00020. [DOI] [PubMed] [Google Scholar]
  14. Marceau F. Kinin B1 receptors: a review. Immunopharmacology. 1995 Jun;30(1):1–26. doi: 10.1016/0162-3109(95)00011-h. [DOI] [PubMed] [Google Scholar]
  15. Marceau F., Levesque L., Drapeau G., Rioux F., Salvino J. M., Wolfe H. R., Seoane P. R., Sawutz D. G. Effects of peptide and nonpeptide antagonists of bradykinin B2 receptors on the venoconstrictor action of bradykinin. J Pharmacol Exp Ther. 1994 Jun;269(3):1136–1143. [PubMed] [Google Scholar]
  16. Menke J. G., Borkowski J. A., Bierilo K. K., MacNeil T., Derrick A. W., Schneck K. A., Ransom R. W., Strader C. D., Linemeyer D. L., Hess J. F. Expression cloning of a human B1 bradykinin receptor. J Biol Chem. 1994 Aug 26;269(34):21583–21586. [PubMed] [Google Scholar]
  17. Nakashima M., Mombouli J. V., Taylor A. A., Vanhoutte P. M. Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries. J Clin Invest. 1993 Dec;92(6):2867–2871. doi: 10.1172/JCI116907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nakhostine N., Ribuot C., Lamontagne D., Nadeau R., Couture R. Mediation by B1 and B2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs. Br J Pharmacol. 1993 Sep;110(1):71–76. doi: 10.1111/j.1476-5381.1993.tb13773.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pelc L. R., Gross G. J., Warltier D. C. Mechanism of coronary vasodilation produced by bradykinin. Circulation. 1991 Jun;83(6):2048–2056. doi: 10.1161/01.cir.83.6.2048. [DOI] [PubMed] [Google Scholar]
  20. Pruneau D., Bélichard P. Induction of bradykinin B1 receptor-mediated relaxation in the isolated rabbit carotid artery. Eur J Pharmacol. 1993 Aug 3;239(1-3):63–67. doi: 10.1016/0014-2999(93)90976-o. [DOI] [PubMed] [Google Scholar]
  21. Pruneau D., Duvoid A., Luccarini J. M., Bélichard P., Bonnafous J. C. The kinin B1 receptor antagonist des-Arg9-[Leu8]bradykinin: an antagonist of the angiotensin AT1 receptor which also binds to the AT2 receptor. Br J Pharmacol. 1995 Jan;114(1):115–118. doi: 10.1111/j.1476-5381.1995.tb14914.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pruneau D., Luccarini J. M., Defrêne E., Paquet J. L., Bélichard P. Pharmacological evidence for a single bradykinin B2 receptor in the guinea-pig. Br J Pharmacol. 1995 Oct;116(3):2106–2112. doi: 10.1111/j.1476-5381.1995.tb16418.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pruneau D., Luccarini J. M., Robert C., Bélichard P. Induction of kinin B1 receptor-dependent vasoconstriction following balloon catheter injury to the rabbit carotid artery. Br J Pharmacol. 1994 Apr;111(4):1029–1034. doi: 10.1111/j.1476-5381.1994.tb14847.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Regoli D. C., Marceau F., Lavigne J. Induction of beta 1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. Eur J Pharmacol. 1981 Apr 24;71(1):105–115. doi: 10.1016/0014-2999(81)90391-5. [DOI] [PubMed] [Google Scholar]
  25. Regoli D., Barabé J., Park W. K. Receptors for bradykinin in rabbit aortae. Can J Physiol Pharmacol. 1977 Aug;55(4):855–867. doi: 10.1139/y77-115. [DOI] [PubMed] [Google Scholar]
  26. Regoli D. Neurohumoral regulation of precapillary vessels: the kallikrein-kinin system. J Cardiovasc Pharmacol. 1984;6 (Suppl 2):S401–S412. doi: 10.1097/00005344-198406002-00015. [DOI] [PubMed] [Google Scholar]
  27. Rhaleb N. E., Dion S., Barabé J., Rouissi N., Jukic D., Drapeau G., Regoli D. Receptors for kinins in isolated arterial vessels of dogs. Eur J Pharmacol. 1989 Mar 29;162(3):419–427. doi: 10.1016/0014-2999(89)90332-4. [DOI] [PubMed] [Google Scholar]
  28. Ribuot C., Godin D., Couture R., Regoli D., Nadeau R. In vivo B2-receptor-mediated negative chronotropic effect of bradykinin in canine sinus node. Am J Physiol. 1993 Sep;265(3 Pt 2):H876–H879. doi: 10.1152/ajpheart.1993.265.3.H876. [DOI] [PubMed] [Google Scholar]
  29. Santiago J. A., Garrison E. A., Kadowitz P. J. Analysis of responses to bradykinin: effects of Hoe-140 in the hindquarters vascular bed of the cat. Am J Physiol. 1994 Aug;267(2 Pt 2):H828–H836. doi: 10.1152/ajpheart.1994.267.2.H828. [DOI] [PubMed] [Google Scholar]
  30. Staszewska-Woolley J., Woodman O. L. Kinin receptors mediating the effects of bradykinin on the coronary circulation in anaesthetized greyhounds. Eur J Pharmacol. 1991 Apr 10;196(1):9–14. doi: 10.1016/0014-2999(91)90402-c. [DOI] [PubMed] [Google Scholar]
  31. Toda N., Bian K., Akiba T., Okamura T. Heterogeneity in mechanisms of bradykinin action in canine isolated blood vessels. Eur J Pharmacol. 1987 Mar 31;135(3):321–329. doi: 10.1016/0014-2999(87)90681-9. [DOI] [PubMed] [Google Scholar]
  32. Wong P. C., Hart S. D., Duncia J. V., Timmermans P. B. Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs. Eur J Pharmacol. 1991 Sep 24;202(3):323–330. doi: 10.1016/0014-2999(91)90274-t. [DOI] [PubMed] [Google Scholar]
  33. Wynsen J. C., Gross G. J., Brooks H. L., Warltier D. C. Changes in adrenergic pressor responses by calcium channel modulation in conscious dogs. Am J Physiol. 1987 Sep;253(3 Pt 2):H531–H539. doi: 10.1152/ajpheart.1987.253.3.H531. [DOI] [PubMed] [Google Scholar]
  34. Yen M. H., Lai C. S. Mechanism of contractile responses to bradykinin in canine basilar arteries. Eur J Pharmacol. 1992 Oct 20;221(2-3):261–266. doi: 10.1016/0014-2999(92)90711-c. [DOI] [PubMed] [Google Scholar]
  35. deBlois D., Bouthillier J., Marceau F. Pulse exposure to protein synthesis inhibitors enhances vascular responses to des-Arg9-bradykinin: possible role of interleukin-1. Br J Pharmacol. 1991 May;103(1):1057–1066. doi: 10.1111/j.1476-5381.1991.tb12300.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES